Mann Chandavimol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mann Chandavimol has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
Tawai Ngernsritrakul
Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
4 shared publications- Ammarin Thakkinstian
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
3 shared publications Krissada Meemook
Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
3 shared publications- Krissada Meemook
Ramathibodi Hospital
3 shared publications - Nakarin Sansanayudh
Cardiology Unit, Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, Thailand
3 shared publications - Suphot Srimahachota
Division of cardiovascular Medicine, Department of Medicine, King Chulalongkorn Memorial Hospital, Thailand
3 shared publications
Latest Publications
- 25 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (8) , e016918
Risk of Aortic Root Rupture in Bicuspid Aortic Stenosis: The ABC Sizing Algorithm for SAPIEN 3 Valves
BACKGROUND: This study evaluated the ability of the ABC Bicuspid Sizing Algorithm to predict aortic root rupture in patients treated with transcatheter aortic valve replacement using SAPIEN 3 valves. METHODS: We conducted a retrospective multicenter study among 15 centers in 7 countries of aortic root rupture cases and controls without root complications. Computed tomography analysis was performed blinded to rupture status. The ABC algorithm was applied to classify risk (high-risk criteria): (1) annular oversizing >10%, (2) intercommissural distance − valve diameter ≤1 mm, (3) maximum sinus diameter − valve diameter 1000 mm 3 and raphe + contralateral or ipsilateral leaflet calcium volume >800 mm 3 , (5) protruding nodular intercommissural distance calcium or full-length calcification of both leaflet edges. RESULTS: A total of 170 patients were included (23 ruptures and 147 controls). Cases exhibited higher total calcium volume (median: 1498 mm 3 versus 826 mm 3 ; P P =0.009), smaller maximum sinus difference (median: 6.79 versus 9.19 mm; P P =0.047). The presence of any high-risk criterion had a sensitivity of 100% (95% CI, 85.7%–100%) and a specificity of 89.1% (95% CI, 83.1%–93.2%) for the identification of rupture cases. The diagnostic odds ratio was 374.5 (95% CI, 21.7–6459.9), with a positive likelihood ratio of 9.19 and a negative likelihood ratio of 0.023. CONCLUSIONS: High calcium volume, narrow sinus dimensions, and excessive valve oversizing were associated with aortic root rupture. The ABC algorithm showed promising performance for risk stratification of patients with bicuspid anatomy being considered for treatment with a SAPIEN 3 valve.
- 25 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (8) , e016918
Risk of Aortic Root Rupture in Bicuspid Aortic Stenosis: The ABC Sizing Algorithm for SAPIEN 3 Valves
BACKGROUND: This study evaluated the ability of the ABC Bicuspid Sizing Algorithm to predict aortic root rupture in patients treated with transcatheter aortic valve replacement using SAPIEN 3 valves. METHODS: We conducted a retrospective multicenter study among 15 centers in 7 countries of aortic root rupture cases and controls without root complications. Computed tomography analysis was performed blinded to rupture status. The ABC algorithm was applied to classify risk (high-risk criteria): (1) annular oversizing >10%, (2) intercommissural distance − valve diameter ≤1 mm, (3) maximum sinus diameter − valve diameter 1000 mm 3 and raphe + contralateral or ipsilateral leaflet calcium volume >800 mm 3 , (5) protruding nodular intercommissural distance calcium or full-length calcification of both leaflet edges. RESULTS: A total of 170 patients were included (23 ruptures and 147 controls). Cases exhibited higher total calcium volume (median: 1498 mm 3 versus 826 mm 3 ; P P =0.009), smaller maximum sinus difference (median: 6.79 versus 9.19 mm; P P =0.047). The presence of any high-risk criterion had a sensitivity of 100% (95% CI, 85.7%–100%) and a specificity of 89.1% (95% CI, 83.1%–93.2%) for the identification of rupture cases. The diagnostic odds ratio was 374.5 (95% CI, 21.7–6459.9), with a positive likelihood ratio of 9.19 and a negative likelihood ratio of 0.023. CONCLUSIONS: High calcium volume, narrow sinus dimensions, and excessive valve oversizing were associated with aortic root rupture. The ABC algorithm showed promising performance for risk stratification of patients with bicuspid anatomy being considered for treatment with a SAPIEN 3 valve.
- Open Access
- 13 April 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (27) , 108149
Early Experience With the Septal Scoring Along the Midline Endocardium (SESAME) Technique in the Asia-Pacific Region
- 13 April 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (27) , 108149
Open AccessEarly Experience With the Septal Scoring Along the Midline Endocardium (SESAME) Technique in the Asia-Pacific Region
- Open Access
- 8 February 2026
- Published by Foundation for Orphan and Rare Lung Disease (FORLD) in The ASEAN Journal of Radiology
- Vol. 27 (1) , 44-64
Efficacy, safety, and optimal use of isoosmolar contrast medium (Iodixanol) in diagnostic and interventional procedures: A Thai multidisciplinary expert meeting report
Contrast media are used in clinical practice for diagnostic and therapeutic purposes. To discuss the position of iso-osmolar contrast media (IOCM) in diagnostic and interventional procedures in Thailand, an expert advice meeting, including neurologists, cardiologists, nephrologists, radiologists, radiologic technologists and radiologic nurses, was organized to discuss the use of IOCM and low-osmolar contrast media, in general and in specific risk groups. Topics discussed included acute kidney injury, cardiovascular events, patient discomfort, allergic reactions, and high-risk groups. The experts agreed that IOCM has an overall beneficial safety profile as compared to low-osmolar contrast media. With the use of IOCM, patients have a low risk of allergic reactions, and a reduced risk of contrast-associated acute kidney injury. Moreover, the patient will feel less pain. Therefore, IOCM is considered particularly useful in patients at high risk of acute kidney injury, especially in procedures that involve significant contrast exposure.
- 8 February 2026
- Published by Foundation for Orphan and Rare Lung Disease (FORLD) in The ASEAN Journal of Radiology
- Vol. 27 (1) , 44-64
Open AccessEfficacy, safety, and optimal use of isoosmolar contrast medium (Iodixanol) in diagnostic and interventional procedures: A Thai multidisciplinary expert meeting report
Contrast media are used in clinical practice for diagnostic and therapeutic purposes. To discuss the position of iso-osmolar contrast media (IOCM) in diagnostic and interventional procedures in Thailand, an expert advice meeting, including neurologists, cardiologists, nephrologists, radiologists, radiologic technologists and radiologic nurses, was organized to discuss the use of IOCM and low-osmolar contrast media, in general and in specific risk groups. Topics discussed included acute kidney injury, cardiovascular events, patient discomfort, allergic reactions, and high-risk groups. The experts agreed that IOCM has an overall beneficial safety profile as compared to low-osmolar contrast media. With the use of IOCM, patients have a low risk of allergic reactions, and a reduced risk of contrast-associated acute kidney injury. Moreover, the patient will feel less pain. Therefore, IOCM is considered particularly useful in patients at high risk of acute kidney injury, especially in procedures that involve significant contrast exposure.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Cardiology
- Vol. 2026 (1)
Three‐Dimensional Printing of Cardiac Reconstruction, Facilitating Customized Closure Device of Gigantic Left Atrial Appendage: Case Report
We present a successful case of 3D printed cardiac reconstruction for a custom‐made LAAO LAmbre (Lifetech Scientific Corp., Shenzhen, China) device of gigantic and challenging LAA anatomy.
- 1 January 2026
- Published by Wiley in Case Reports in Cardiology
- Vol. 2026 (1)
Open AccessThree‐Dimensional Printing of Cardiac Reconstruction, Facilitating Customized Closure Device of Gigantic Left Atrial Appendage: Case Report
We present a successful case of 3D printed cardiac reconstruction for a custom‐made LAAO LAmbre (Lifetech Scientific Corp., Shenzhen, China) device of gigantic and challenging LAA anatomy.
- Open Access
- 23 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7505
Consensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention Association of Thailand
Background: Drug-coated balloons (DCBs) have transformed percutaneous coronary intervention (PCI) by delivering antiproliferative drugs without leaving a permanent scaffold. DCB is initially indicated for in-stent restenosis (ISR) and now has expanded indication for treating small vessel disease and bifurcation lesions. However, there is a heterogeneity in the patient and lesion selection, lesion preparation techniques, and the optimal duration of dual antiplatelet therapy after DCB angioplasty. The Cardiovascular Intervention Association of Thailand (CIAT) developed a consensus statement on DCB use in coronary interventions. Methods: The CIAT expert panel systematically reviewed randomized controlled trials, meta-analyses, and real-world studies evaluating DCB therapy. Procedural strategies, imaging guidance, physiologic assessment, and antiplatelet therapy protocols were appraised. The recommendations were developed and put to an online vote. Consensus was defined when the recommendation reached 80% of votes in support of “agree” or “neutral”. Results: Clinical evidence demonstrates that DCBs achieve comparable outcomes to drug-eluting stents (DESs) in selected lesions while enabling shorter durations of dual antiplatelet therapy (DAPT), particularly beneficial for high-bleeding-risk patients. Optimal outcomes require meticulous lesion preparation, appropriate balloon sizing, and controlled vessel dissection. Intravascular imaging and physiologic assessment further refine procedural precision, while hybrid strategies combining DCBs and DESs address complex lesions and multivessel disease. The final document presents 15 consensus statements addressing indications, procedural techniques, imaging and physiologic guidance, and antiplatelet therapy recommendations. Conclusions: DCB angioplasty can be an alternative or complement to therapeutic options to DESs across multiple clinical and anatomical scenarios. The CIAT consensus provided structured recommendations to support DCB therapy in contemporary practice.
- 23 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7505
Open AccessConsensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention Association of Thailand
Background: Drug-coated balloons (DCBs) have transformed percutaneous coronary intervention (PCI) by delivering antiproliferative drugs without leaving a permanent scaffold. DCB is initially indicated for in-stent restenosis (ISR) and now has expanded indication for treating small vessel disease and bifurcation lesions. However, there is a heterogeneity in the patient and lesion selection, lesion preparation techniques, and the optimal duration of dual antiplatelet therapy after DCB angioplasty. The Cardiovascular Intervention Association of Thailand (CIAT) developed a consensus statement on DCB use in coronary interventions. Methods: The CIAT expert panel systematically reviewed randomized controlled trials, meta-analyses, and real-world studies evaluating DCB therapy. Procedural strategies, imaging guidance, physiologic assessment, and antiplatelet therapy protocols were appraised. The recommendations were developed and put to an online vote. Consensus was defined when the recommendation reached 80% of votes in support of “agree” or “neutral”. Results: Clinical evidence demonstrates that DCBs achieve comparable outcomes to drug-eluting stents (DESs) in selected lesions while enabling shorter durations of dual antiplatelet therapy (DAPT), particularly beneficial for high-bleeding-risk patients. Optimal outcomes require meticulous lesion preparation, appropriate balloon sizing, and controlled vessel dissection. Intravascular imaging and physiologic assessment further refine procedural precision, while hybrid strategies combining DCBs and DESs address complex lesions and multivessel disease. The final document presents 15 consensus statements addressing indications, procedural techniques, imaging and physiologic guidance, and antiplatelet therapy recommendations. Conclusions: DCB angioplasty can be an alternative or complement to therapeutic options to DESs across multiple clinical and anatomical scenarios. The CIAT consensus provided structured recommendations to support DCB therapy in contemporary practice.
- Open Access
- 27 April 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 418-422
Hybrid Transcatheter Pulmonary Valve Replacement With SAPIEN S3 Following Right Ventricular Outflow Tract Reduction Using Tricuspid Annuloplasty Rings
We describe a novel variation of hybrid TPVR using a tricuspid annuloplasty ring which can be considered for patients with very large RVOT, short pulmonary artery, and limited vascular access and to avoid the risk of cardiopulmonary bypass. The utilization of Carpentier‐Edwards Physio Tricuspid annuloplasty ring can reduce the size of the RVOT and at the same time the ring served as an effective docking site for the implantation of the SAPIEN S3 (Edwards Lifesciences). All three reported cases showed satisfactory immediate hemodynamic and clinical outcomes as well as at mid‐term follow up.
- 27 April 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 418-422
Open AccessHybrid Transcatheter Pulmonary Valve Replacement With SAPIEN S3 Following Right Ventricular Outflow Tract Reduction Using Tricuspid Annuloplasty Rings
We describe a novel variation of hybrid TPVR using a tricuspid annuloplasty ring which can be considered for patients with very large RVOT, short pulmonary artery, and limited vascular access and to avoid the risk of cardiopulmonary bypass. The utilization of Carpentier‐Edwards Physio Tricuspid annuloplasty ring can reduce the size of the RVOT and at the same time the ring served as an effective docking site for the implantation of the SAPIEN S3 (Edwards Lifesciences). All three reported cases showed satisfactory immediate hemodynamic and clinical outcomes as well as at mid‐term follow up.
- Open Access
- 14 March 2025
- Published by Wiley
Three-Dimensional Printing of Cardiac Reconstruction, Facilitating Customized Closure Device of Gigantic Left Atrial Appendage: Case Report
- 14 March 2025
- Published by Wiley
Open AccessThree-Dimensional Printing of Cardiac Reconstruction, Facilitating Customized Closure Device of Gigantic Left Atrial Appendage: Case Report
- Open Access
- 1 November 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Asian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis
Transcatheter aortic valve implantation (TAVI) has been established as an effective treatment modality in patients with severe aortic stenosis and the uptake of TAVI is rapidly growing in the Asia-Pacific region. However, there exists a heterogeneity in the management of aortic stenosis and the use of TAVI among countries in the region. Reasons for these differences include anatomical variations, disparity in healthcare resources and infrastructure and the lack of consensus on the optimal management of aortic stenosis in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group, including a multidisciplinary group of general and interventional cardiologists, cardiac surgeons and imaging specialists, developed a position statement on the recommendations for TAVI in the management of aortic stenosis. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral.’ The resulting 28 statements provide guidance for clinical practitioners in the region on the use of TAVI in the treatment of patients with aortic stenosis.
- 1 November 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Open AccessAsian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis
Transcatheter aortic valve implantation (TAVI) has been established as an effective treatment modality in patients with severe aortic stenosis and the uptake of TAVI is rapidly growing in the Asia-Pacific region. However, there exists a heterogeneity in the management of aortic stenosis and the use of TAVI among countries in the region. Reasons for these differences include anatomical variations, disparity in healthcare resources and infrastructure and the lack of consensus on the optimal management of aortic stenosis in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group, including a multidisciplinary group of general and interventional cardiologists, cardiac surgeons and imaging specialists, developed a position statement on the recommendations for TAVI in the management of aortic stenosis. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral.’ The resulting 28 statements provide guidance for clinical practitioners in the region on the use of TAVI in the treatment of patients with aortic stenosis.
- Open Access
- 20 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (16) , e031433
Impact of Procedural Success Definitions on Long‐Term Outcomes in Patients With Rheumatic Mitral Stenosis Treated With Percutaneous Balloon Mitral Valvuloplasty: A Multicenter, Retrospective Cohort Study
Background: It is uncertain which percutaneous balloon mitral valvuloplasty (PBMV) success definitions should be used because there are no studies comparing the effects of these definitions on subsequent outcomes. We evaluated the association between 3 success definitions and long‐term clinical outcomes in patients with rheumatic mitral stenosis who underwent PBMV. Methods and Results: This multicenter retrospective study included patients with severe rheumatic mitral stenosis who underwent PBMV. Three definitions were used as follows: (A) post‐PBMV mitral valve area (MVA) ≥1.5 cm 2 or ≥50% increase in MVA with MR 2 and MR ≤2+; and (C) post‐PBMV MVA ≥1.5 cm 2 or ≥50% increase in MVA, with no more than 1‐grade increment in MR. Multivariable Cox regression analyses were performed to evaluate the associations between PBMV success and the composite of all‐cause mortality, mitral surgery, and repeat PBMV. Successful PBMV, according to definitions A, B, and C was associated with a lower risk of the composite outcomes (definition A—hazard ratio [HR], 0.55 [95% CI, 0.43–0.69], definition B—HR, 0.55 [95% CI, 0.43–0.69], definition C—HR, 0.55 [95% CI, 0.44–0.69]). Patients meeting all 3 success definitions had the lowest risk compared with those who did not meet any definition or met 1 or 2 definitions. Conclusions: All 3 success definitions had a prognostic impact on outcomes. Patients who achieved post‐PBMV MVA ≥1.5 cm 2 , irrespective of the percentage increase in MVA, and MR ≤grade 2, with no more than a 1‐grade increment in MR, had the most favorable outcomes.
- 20 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (16) , e031433
Open AccessImpact of Procedural Success Definitions on Long‐Term Outcomes in Patients With Rheumatic Mitral Stenosis Treated With Percutaneous Balloon Mitral Valvuloplasty: A Multicenter, Retrospective Cohort Study
Background: It is uncertain which percutaneous balloon mitral valvuloplasty (PBMV) success definitions should be used because there are no studies comparing the effects of these definitions on subsequent outcomes. We evaluated the association between 3 success definitions and long‐term clinical outcomes in patients with rheumatic mitral stenosis who underwent PBMV. Methods and Results: This multicenter retrospective study included patients with severe rheumatic mitral stenosis who underwent PBMV. Three definitions were used as follows: (A) post‐PBMV mitral valve area (MVA) ≥1.5 cm 2 or ≥50% increase in MVA with MR 2 and MR ≤2+; and (C) post‐PBMV MVA ≥1.5 cm 2 or ≥50% increase in MVA, with no more than 1‐grade increment in MR. Multivariable Cox regression analyses were performed to evaluate the associations between PBMV success and the composite of all‐cause mortality, mitral surgery, and repeat PBMV. Successful PBMV, according to definitions A, B, and C was associated with a lower risk of the composite outcomes (definition A—hazard ratio [HR], 0.55 [95% CI, 0.43–0.69], definition B—HR, 0.55 [95% CI, 0.43–0.69], definition C—HR, 0.55 [95% CI, 0.44–0.69]). Patients meeting all 3 success definitions had the lowest risk compared with those who did not meet any definition or met 1 or 2 definitions. Conclusions: All 3 success definitions had a prognostic impact on outcomes. Patients who achieved post‐PBMV MVA ≥1.5 cm 2 , irrespective of the percentage increase in MVA, and MR ≤grade 2, with no more than a 1‐grade increment in MR, had the most favorable outcomes.
- Open Access
The Incidence, Predictors, and Mortality Impact of Ventricular Pacing Dependency after Transcatheter Aortic Valve Replacement: A Prospective Cohort
Background: Atrioventricular conduction disturbance occurs in a significant number of patients underwent transcatheter aortic valve replacement (TAVR). However, not all of the cases persistently depend on ventricular pacing. Objective: To study the incidence, predictors, and outcomes of new ventricular pacing dependency (VpDep) after TAVR. Design: Prospective, single-center, cohort trial Methods: The first 130 consecutive transfemoral TAVR cases, except 3 with prior cardiac electronic implantable devices (CIEDs) who depended on ventricular pacing, were analyzed. The endpoints were VpDep at 1 month and all-cause mortality at the end of follow-up in 2021. The effects of variables on VpDep and all-cause mortality were evaluated using multivariate binary logistic regression and Cox-regression analysis, respectively. First degree atrioventricular block (AVB) was considered severe when PR interval > 300 ms. Results: Out of 127 patients in the analysis (mean age 82 years, SD 6.3; 62.2% female sex; 67.7% Balloon-expandable device), 7 patients (5.5%) had implanted with CIEDs before TAVR but not ventricular pacing dependent. The incidence of VpDep at 1 month was 7.9% (n=10) among all patients and 34.5% among patients with CIEDs (n=29). VpDep was likely to occur in patients with pre-existing right bundle branch block (OR 21.38; 95% CI 3.25-139.33; P=.001) and severe 1 st degree or Mobitz I AVB (OR 14.79; 95% CI 1.65-132.74; P=.016). After a mean follow-up of 25.8 months (SD 21.2), death from any causes occurred in 18 patients (14.2%). VpDep was not associated with excess mortality. Conclusion: VpDep at 1 month occurred in 7.9% of all patients underwent TAVR. Pre-existing conduction abnormalities were significantly associated with higher risk of VpDep. Mortality was similar between patients with and without VpDep. Clinical Trial Registration: Thai Clinical Trial Registration; Study ID: TCTR20220726005
Open AccessThe Incidence, Predictors, and Mortality Impact of Ventricular Pacing Dependency after Transcatheter Aortic Valve Replacement: A Prospective Cohort
Background: Atrioventricular conduction disturbance occurs in a significant number of patients underwent transcatheter aortic valve replacement (TAVR). However, not all of the cases persistently depend on ventricular pacing. Objective: To study the incidence, predictors, and outcomes of new ventricular pacing dependency (VpDep) after TAVR. Design: Prospective, single-center, cohort trial Methods: The first 130 consecutive transfemoral TAVR cases, except 3 with prior cardiac electronic implantable devices (CIEDs) who depended on ventricular pacing, were analyzed. The endpoints were VpDep at 1 month and all-cause mortality at the end of follow-up in 2021. The effects of variables on VpDep and all-cause mortality were evaluated using multivariate binary logistic regression and Cox-regression analysis, respectively. First degree atrioventricular block (AVB) was considered severe when PR interval > 300 ms. Results: Out of 127 patients in the analysis (mean age 82 years, SD 6.3; 62.2% female sex; 67.7% Balloon-expandable device), 7 patients (5.5%) had implanted with CIEDs before TAVR but not ventricular pacing dependent. The incidence of VpDep at 1 month was 7.9% (n=10) among all patients and 34.5% among patients with CIEDs (n=29). VpDep was likely to occur in patients with pre-existing right bundle branch block (OR 21.38; 95% CI 3.25-139.33; P=.001) and severe 1 st degree or Mobitz I AVB (OR 14.79; 95% CI 1.65-132.74; P=.016). After a mean follow-up of 25.8 months (SD 21.2), death from any causes occurred in 18 patients (14.2%). VpDep was not associated with excess mortality. Conclusion: VpDep at 1 month occurred in 7.9% of all patients underwent TAVR. Pre-existing conduction abnormalities were significantly associated with higher risk of VpDep. Mortality was similar between patients with and without VpDep. Clinical Trial Registration: Thai Clinical Trial Registration; Study ID: TCTR20220726005